| Literature DB >> 35551058 |
Tristan J Philippe1,2, Naureen Sikder3, Anna Jackson4, Maya E Koblanski1,5, Eric Liow6, Andreas Pilarinos6,7, Krisztina Vasarhelyi6,8.
Abstract
BACKGROUND: The COVID-19 pandemic has shifted mental health care delivery to digital platforms, videoconferencing, and other mobile communications. However, existing reviews of digital health interventions are narrow in scope and focus on a limited number of mental health conditions.Entities:
Keywords: COVID-19; computer-assisted therapy; digital health; mental health; mobile applications; mobile apps; online therapy; telemedicine; telepsychiatry; telepsychology; virtual reality exposure therapy
Year: 2022 PMID: 35551058 PMCID: PMC9109782 DOI: 10.2196/35159
Source DB: PubMed Journal: JMIR Ment Health ISSN: 2368-7959
Figure 1PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) flowchart for study selection.
Metadata per mental health condition examining article and participant numbers.
| Mental health conditions | Total literaturea, n | Secondary literatureb, n | Primary literaturec, n | Participants, n (%) |
| Attention-deficit/hyperactivity disorder | 90 | 8 | 35 | 2428 (0.5) |
| Anxiety, mood, stress, trauma | 1205 | 123 | 923 | 136,121 (29.5) |
| Bipolar and related disorders | 65 | 9 | 42 | 3573 (0.8) |
| Dementia | 246 | 24 | 180 | 10,823 (2.3) |
| Developmental disorders (excluding attention-deficit/hyperactivity disorder) | 326 | 24 | 349 | 8736 (1.9) |
| Feeding and eating disorders | 154 | 23 | 117 | 10,441 (2.3) |
| Pain | 147 | 23 | 348 | 24,327 (5.3) |
| Schizophrenia and psychotic disorders | 263 | 30 | 304 | 20,500 (4.4) |
| Sleep-wake disorders | 145 | 8 | 29 | 3333 (0.7) |
| Substance-related disorders | 555 | 59 | 466 | 241,377 (52.3) |
aTotal number of articles from Medline searches.
bSelected secondary literature.
cPrimary literature curated by secondary sources.
Figure 2Number of included articles per year.
Digital health interventions used to treat mental health conditions.
| Condition | Therapist contact | Online peer support | Web-based therapy | Mobile therapy | Virtual reality | Cognitive training | |||||||
|
| |||||||||||||
|
| RCT-TAUa (patients/studies), n/n | 45/1 | —b | — | — | — | 363/4 | ||||||
|
| RTC-otherc (patients/studies), n/n | 968/6 | — | — | — | — | 929/14 | ||||||
|
| Observational (patients/studies), n/n | 45/4 | — | — | — | 2/1 | 36/5 | ||||||
|
| Reported study quality (1=low to 3=high) | Not reported | — | — | — | 1.00 | 1.00 | ||||||
|
| Overall strength of evidenced | Medium | — | — | — | Low | Medium | ||||||
|
| Effective as treatment modality?e | Yes | — | — | — | Emerging | Inconclusive | ||||||
|
| Effective as assessment modality?e | Yes [ | — | — | — | Emerging [ | Inconclusive [ | ||||||
|
| |||||||||||||
|
| RCT-TAU (patients/studies), n/n | 7156/60 | — | 19,803/105 | 1333/6 | 2842/65 | 42/3 | ||||||
|
| RTC-other (patients/studies), n/n | 5460/38 | 73/1 | 51,074/279 | 3905/22 | 2974/69 | 222/6 | ||||||
|
| Observational (patients/studies), n/n | 1567/41 | — | 31,461/93 | 45/1 | 305/21 | — | ||||||
|
| Reported study quality (1=low to 3=high) | 2.33 (SD 0.57) | Not reported | 2.38 (SD 0.68) | 1.64 (SD 0.64) | 1.78 (SD 0.68) | 1.00 | ||||||
|
| Overall strength of evidence | High | Low | High | Medium | High | Low | ||||||
|
| Effective as treatment modality? | Yes | Emerging | Yes | Yes | Yes | Emerging | ||||||
|
| Effective as assessment modality? | Yes [ | No studies [ | Emerging [ | Yes [ | Emerging [ | Emerging [ | ||||||
|
| |||||||||||||
|
| RCT-TAU (patients/studies), n/n | — | — | 992/14 | 132/1 | — | — | ||||||
|
| RTC-other (patients/studies), n/n | 14/1 | 286/3 | 1499/7 | — | — | — | ||||||
|
| Observational (patients/studies), n/n | —/3 | 156/1 | 273/5 | 51/1 | — | — | ||||||
|
| Reported study quality (1=low to 3=high) | Not reported | 1.00 | 1.00 | 2.75 | — | — | ||||||
|
| Overall strength of evidence | Low | Medium | Medium | Low | — | — | ||||||
|
| Effective as treatment modality? | Yes | Emerging | Noj | Emerging | — | — | ||||||
|
| Effective as assessment modality? | Yes [ | No studies [ | No studies [ | No studies [ | [ | — | ||||||
|
| |||||||||||||
|
| RCT-TAU (patients/studies), n/n | 483/6 | — | — | 3981/7 | 331/11 | 590/16 | ||||||
|
| RTC-other (patients/studies), n/n | 486/4 | — | — | —/30 | 30/1 | 1222/19 | ||||||
|
| Observational (patients/studies), n/n | 1695/29 | — | — | —/30 | 273/10 | 282/16 | ||||||
|
| Reported study quality (1=low to 3=high) | 1.75 (SD 0.75) | — | — | Not reported | 1.50 (SD 0.50) | 1.63 (SD 0.41) | ||||||
|
| Overall strength of evidence | Medium | — | — | Medium | Medium | Medium | ||||||
|
| Effective as treatment modality? | Yes | — | — | Yes | Inconclusive | Yes | ||||||
|
| Effective as assessment modality? | Yes [ | — | — | Yes [ | No studies [ | Yes [ | ||||||
|
| |||||||||||||
|
| RCT-TAU (patients/studies), n/n | 773/8 | 11/1 | 1054/10 | — | — | — | ||||||
|
| RTC-other (patients/studies), n/n | 1019/10 | 384/4 | 2852/17 | — | — | — | ||||||
|
| Observational (patients/studies), n/n | 78/3 | 54/2 | 176/6 | — | — | — | ||||||
|
| Reported study quality (1=low to 3=high) | 1.50 | 1.50 | 1.50 | — | — | — | ||||||
|
| Overall strength of evidence | Medium | Low | Medium | — | — | — | ||||||
|
| Effective as treatment modality? | Yes | Emerging | Yes | — | — | — | ||||||
|
| Effective as assessment modality? | Yes [ | No studies [ | Emerging [ | — | — | — | ||||||
|
| |||||||||||||
|
| RCT-TAU (patients/studies), n/n | 535/13 | — | — | 107/4 | 222/7 | 984/20 | ||||||
|
| RTC-other (patients/studies), n/n | 327/10 | — | 80/3 | 69/3 | 877/24 | 1298/55 | ||||||
|
| Observational (patients/studies), n/n | 3330/88 | — | 7/1 | 7/2 | 212/24 | 392/37 | ||||||
|
| Reported study quality (1=low to 3=high) | 1.56 (SD 0.77) | — | 1.00 | 1.50 | 2.50 (SD 0.50) | 1.00 (SD 0) | ||||||
|
| Overall strength of evidence | High | — | Low | Low | Medium | High | ||||||
|
| Effective as treatment modality? | Yes | — | Inconclusive | Inconclusive | Inconclusive | Yes | ||||||
|
| Effective as assessment modality? | Yes [ | — | No studies [ | No studies [ | No studies [ | Yes [ | ||||||
|
| |||||||||||||
|
| RCT-TAU (patients/studies), n/n | 833/15 | — | 2497/23 | 276/3 | 628/9 | — | ||||||
|
| RTC-other (patients/studies), n/n | 97/1 | 275/3 | 3361/29 | 143/3 | — | — | ||||||
|
| Observational (patients/studies), n/n | 296/8 | — | 1928/18 | 107/5 | — | — | ||||||
|
| Reported study quality (1=low to 3=high) | 2.00 | 2.00 | 1.83 (SD 0.69) | 1.00 | 1.00 | — | ||||||
|
| Overall strength of evidence | Medium | Medium | High | Medium | Medium | — | ||||||
|
| Effective as treatment modality? | Yes | Emerging | Yes | Emerging | Yes | — | ||||||
|
| Effective as assessment modality? | Yes [ | No studies [ | Emerging [ | Emerging [ | No studies [ | N/A | ||||||
|
| |||||||||||||
|
| RCT-TAU (patients/studies), n/n | 4350/54 | — | 1339/10 | 0 | 3583/43 | — | ||||||
|
| RTC-other (patients/studies), n/n | 3203/46 | — | 5666/37 | — | 2642/35 | — | ||||||
|
| Observational (patients/studies), n/n | 2066/66 | — | — | — | 1478/56 | — | ||||||
|
| Reported study quality (1=low to 3=high) | 1.42 (SD 0.55) | — | 2.0 (SD 0.71) | — | 1.21 (SD 0.37) | — | ||||||
|
| Overall strength of evidence | High | — | High | — | High | — | ||||||
|
| Effective as treatment modality? | Yes | — | Yes | — | Yes | — | ||||||
|
| Effective as assessment modality? | No studies [ | — | Emerging [ | — | No studies [ | — | ||||||
|
| |||||||||||||
|
| RCT-TAU (patients/studies), n/n | — | —/4 | —/9 | 1580/6 | 292/4 | 1495/33 | ||||||
|
| RTC-other (patients/studies), n/n | 3287/5 | —/2 | 101/3 | 5837/4 | 1735/28 | 1783/31 | ||||||
|
| Observational (patients/studies), n/n | 404/5 | —/2 | 20/2 | 1891/23 | 1267/32 | 86/5 | ||||||
|
| Reported study quality (1=low to 3=high) | 1.50 (SD 0.87) | 1.67 (SD 0.94) | 2.00 (SD 1.00) | 1.83 (SD 0.62) | 2.25 (SD 1.0) | 2.50 (SD 0.41) | ||||||
|
| Overall strength of evidence | Medium | Low | Low | Medium | High | High | ||||||
|
| Effective as treatment modality? | Yes | Yes | Yes | Yes | Inconclusive | Yes | ||||||
|
| Effective as assessment modality? | Yes [ | No studies [ | Emerging [ | Emerging [ | No studies [ | Yes [ | ||||||
|
| |||||||||||||
|
| RCT-TAU (patients/studies), n/n | — | — | 1779/9 | — | — | — | ||||||
|
| RTC-other (patients/studies), n/n | — | — | 1220/13 | — | — | — | ||||||
|
| Observational (patients/studies), n/n | — | — | 334/6 | — | — | — | ||||||
|
| Reported study quality (1=low to 3=high) | — | — | 2.00 (SD 0.63) | — | — | — | ||||||
|
| Overall strength of evidence | — | — | Medium | — | — | — | ||||||
|
| Effective as treatment modality? | — | — | No | — | — | — | ||||||
|
| Effective as assessment modality? | — | — | No studies [ | — | — | — | ||||||
|
| |||||||||||||
|
| RCT-TAU (patients/studies), n/n | 8151/21 | — | 61,896/93 | 4650/8 | 11/1 | — | ||||||
|
| RTC-other (patients/studies), n/n | 15,610/31 | — | 97,802/180 | 12,385/22 | 219/5 | — | ||||||
|
| Observational (patients/studies), n/n | 984/5 | — | 14,603/35 | 5231/30 | 181/8 | — | ||||||
|
| Reported study quality (1=low to 3=high) | 2.13 (SD 0.74) | — | 2.07 (SD 0.63) | 2.26 (SD 0.74) | 1.33 (SD 0.47) | — | ||||||
|
| Overall strength of evidence | High | — | High | High | Medium | — | ||||||
|
| Effective as treatment modality? | Yes | — | Yes | Yes | Inconclusive | — | ||||||
|
| Effective as assessment modality? | Yes [ | — | Yes [ | Emerging [ | No studies [ | — | ||||||
|
| |||||||||||||
|
| RCT-TAU (patients/studies), n/n | 22,326/178 | 11/5 | 89,360/273 | 11,927/34 | 7909/140 | 3474/76 | ||||||
|
| RTC-other (patients/studies), n/n | 30,471/152 | 1018/13 | 163,655/569 | 22,521/63 | 8477/162 | 5494/125 | ||||||
|
| Observational (patients/studies), n/n | 10,465/252 | 210/5 | 48,802/166 | 7332/92 | 3718/152 | 796/63 | ||||||
|
| Reported study quality (1=low to 3=high) | 1.69 | 1.54 | 1.86 | 1.83 | 1.64 | 1.45 | ||||||
|
| Overall strength of evidence | High | Low | High | Medium | High | Medium | ||||||
|
| Effective as treatment modality? | Yes | Emerging | Inconclusive | Inconclusive | Inconclusive | Yes | ||||||
|
| Effective as assessment modality? | Yes | No studies | Yes | Emerging | Emerging | Yes | ||||||
aRCT-TAU control: Randomized controlled trials with a treatment-as-usual control.
b—: not determined.
cRCT-other control: Randomized controlled trials with a waitlist or placebo control.
dHigh confidence based on >30 randomized controlled trials with >2000 participants in total; Medium confidence owing to <30 randomized controlled trials with <2000 participants; Low confidence owing to <500 participants; N/A: not applicable.
eYes=positive treatment outcomes and low drop-out rates; Inconclusive=mixed findings, may be effective; Emerging=novel area of research with insufficient evidence; No=no significant difference in outcomes between intervention and controls.
fWeb-based programs developed for bipolar disorders only address depression symptoms but not mania symptoms.
gPatients with schizophrenia and psychotic disorders or symptoms may not be willing to use any digital modalities owing to paranoia about technology, which stems from the underlying psychopathology.